Cellectar Biosciences (FRA:NV4) Change In Payables And Accrued Expense : €0.47 Mil (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Cellectar Biosciences Change In Payables And Accrued Expense?

Cellectar Biosciences's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was €-1.64 Mil. It means Cellectar Biosciences's Accounts Payable & Accrued Expense declined by €1.64 Mil from Dec. 2023 to Mar. 2024 .

Cellectar Biosciences's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was €3.39 Mil. It means Cellectar Biosciences's Accounts Payable & Accrued Expense increased by €3.39 Mil from Dec. 2022 to Dec. 2023 .

Cellectar Biosciences Change In Payables And Accrued Expense Historical Data

The historical data trend for Cellectar Biosciences's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectar Biosciences Change In Payables And Accrued Expense Chart

Cellectar Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

1.01

0.64

0.37

1.53

3.39

Cellectar Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															1.33	-0.47	1.33	1.25	-1.64

Cellectar Biosciences Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.47 Mil.

Cellectar Biosciences Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Cellectar Biosciences's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectar Biosciences (FRA:NV4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectar Biosciences Inc (FRA:NV4) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

CLRB:USA

Address

100 Campus Drive, Florham Park, NJ, USA, 07932

Website

https://www.cellectar.com

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.

Cellectar Biosciences (FRA:NV4) Headlines

No Headlines